MOMM Diagnostics GmbH is a Swiss early stage start-up and the coordinator of the Pathfinder Innovation Launchpad project PEDPOC. This project is developing a new generation prototype for Point-of-care testing (POCT) of Preeclampsia (PE), one of the most common pregnancy complications causing severe threats to mother and baby.

MOMM Diagnostics GmbH is exploiting the new concepts for electrical biosensors developed by Empa, the Swiss federal laboratories for materials science and technology, within the previous FET Open project RECORD-IT.

The innovative technology, based on highly specific immunoassays in combination with electrical biosensor technology, is used by PEDPOC project for the creation of a low-cost single-use cartridge and a hand-held reader for the quantification of multiple preeclampsia biomarkers in serum samples.

The EIC Pathfinder supports MOMM Diagnostics in analyzing the current market of point-of care applications and verifying the potential of the new product for future commercialization in testing Preeclampsia.

The Swiss start-up plans to enter in the market of PE with a POCT product in 2023 with sales reaching 40M CHF within 5 years after market entry. Production, testing on consumers and Research and development will be performed in Switzerland and EU, leading to the creation of 25 jobs.

MOMM Diagnostics CEO, Mathias Wipf, says that ”participating the EIC Pathfinder programme represents a great opportunity to study the feasibility of a scientific result for its application in a marketable project.”

The start-up is also profiting from the business coaching services under EIC and believes that “This is a great opportunity to gain inside know-how and learn how to transform innovation into a product.”